Chest
Volume 140, Issue 4, Supplement, 23–26 October 2011, Page 903A
Slide Presentations: Sunday, October 23, 2011 | October 2011Use of Parenteral Prostanoids at Time of Death in Patients With Pulmonary Arterial Hypertension Enrolled in REVEAL
Section snippets
Abstract
PURPOSE: A primary objective of the Registry to EValuate Early And Long-term Pulmonary Arterial Hypertension (PAH) Disease Management (REVEAL) is to determine outcomes in patients with PAH. Analysis of PAH-specific therapy at time of death could provide information on the aggressiveness of therapy and the adherence to recommended treatment guidelines in patients with the most severe disease. In this study, we compared functional class assessments prior to death and parenteral prostanoid
References (0)
Cited by (0)
Copyright © 2011 The American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.